Compare NIO Inc. (NIO) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NIO Inc. vs ResMed Inc. — how do they compare? NIO Inc. trades at $4.57 (market cap $11.59B), while ResMed Inc. trades at $223.57 (market cap $32.61B). The key difference: ResMed Inc. is far larger — about 2.8× NIO Inc.'s market cap, and ResMed Inc. pays a 1.17% dividend while NIO Inc. pays none. Which is the better fit depends on your goals.
| NIO | RMD | |
|---|---|---|
Market Cap | $11.59B | $32.61B |
Sector | Consumer Cyclical | Health |
52-Week High | $7.89 | $293.73 |
52-Week Low | $4.44 | $182.82 |
Enterprise Value | $10.82B | $31.97B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NIO trades at $4.82, up 1.69% today, showing recent volatility amid mixed market signals. The company reported July 2026 deliveries growth and has beaten earnings expectations for three consecutive quarters, though it remains unprofitable with a net income margin of -9.09%. Technical indicators show neutral momentum with RSI at neutral levels, while analyst sentiment leans bullish with 54% buy ratings.
NIO presents a high-risk growth opportunity with improving revenue trends but persistent losses. The stock offers potential upside if profitability improves, but faces significant execution risks in the competitive EV market. Investors should weigh strong delivery growth against cash burn and negative equity returns before considering position entry.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
